Latest Capital Raisings News

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Activeport Group Ltd’s FY26 results show a 36% revenue decline to $6.15 million and a net loss of $14.7 million, driven by strategic shifts towards recurring software revenue and AI infrastructure orchestration. The company launched its own national network in Australia and expanded internationally with new subsidiaries and leadership hires.

NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Adslot Ltd swung to a $4.2 million profit in FY2026, buoyed by a $6 million non-cash gain from deconsolidating its troubled subsidiary. The company’s restructuring efforts trimmed costs by 28%, but revenue fell 10%.

SportsHero Limited reported a dramatic surge in revenue to AU$1.05 million for FY26, driven by new telco partnerships and the HeroPlay gaming platform launch, while losses increased 29% as the company ramped up marketing and development costs.

The Calmer Co. International Limited posted a record $8.1 million revenue for FY26, driven by retail and wholesale growth, yet recorded a $3.8 million net loss amid ongoing funding challenges and strategic investments.

Pengana Global Private Credit Trust (ASX: PCX) reported a solid FY26 with an 8.8% cash distribution yield and stable credit quality despite fair value pressures from widening credit spreads.

Maggie Beer Holdings reported a 60.8% reduction in net loss for FY26 to $9.5 million despite flat sales, driven by margin gains and cost cuts. The company appointed Chris Illman as Managing Director to lead its recovery and growth strategy.

ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.